Pseudomonas aeruginosa within serogroups previously considered to be serologically homogeneous. We characterized murine monoclonal antibodies (MAbs) and immunization-induced human polyclonal antibodies reactive with one or more of five structurally variant LPS subtypes belonging to serogroup 06 of the International Antigenic Typing System. Analyses of five different MAbs employing purified LPS or whole bacteria in enzyme-linked immunosorbent assays and Western blot (immunoblot) assays revealed five distinct patterns of subtype specificity, ranging from recognition of a single subtype to reactivity with all five. MAb-mediated opsonophagocytic killing and in vivo protection against live challenge in mice correlated, in general, with differential binding to various LPS subtypes. In comparison, sera from human vaccinees immunized with LPS-derived high-molecular-weight polysaccharide from P. aeruginosa Fisher immunotype 1, one of five serogroup 06 subtypes, exhibited LPS binding and opsonic activity against all five subtypes. Antibodies in the human sera effectively inhibited binding to all five LPS subtype antigens of the cross-reactive MAb, LC3-2H2, suggesting the existence of a common serogroup-related epitope. These findings emphasize the importance of defining subtype-associated variations in LPS antigenicity and corresponding differences in antibody specificity and function as a basis for designing immunoprophylactic or therapeutic strategies which target P. aeruginosa LPS.
Protective immunity against infections caused by Pseudomonas aeruginosa is mediated by antibodies to the O-polysaccharide portion of lipopolysaccharides (LPS) residing in the bacterial outer membrane. This has been documented in animal models (3, 4, 26, 33, 38, 50) and in humans (40, 47, 48) . LPS-based vaccines can prevent human Pseudomonas infections (13, 14, 49) , although the use of such vaccines may be associated with local and systemic toxicity. This toxicity is greatly reduced, however, through the use of high-molecularweight polysaccharide derivatives of the LPS 0-side chain (27, 29, 34) or by conjugates composed of LPS 0-side chain and carrier proteins (6, 8, 9) .
Variations in the monosaccharide composition of the 0-polysaccharide portion of the LPS macromolecule provide an antigenic basis for serogrouping P. aeruginosa. The International Antigenic Typing System (IATS), which provides the most comprehensive serotyping scheme for P. aeruginosa, contains 20 major serogroups (22, 23) . Almost all clinical isolates are classifiable with antibodies that recognize these 20 serogroups, and 7 to 10 of the serogroups cause >90% of clinical P. aeruginosa disease (35) .
With detailed characterization of the 0-side chain structures of LPS from different P. aeruginosa serogroups (15, 16) has come a growing recognition of structural and antigenic heter-ogeneity within individual serogroups, giving rise to immunologically distinct subgroups or subtypes (20) . As many as eight variant, subtype-defining, 0-polysaccharide structures have been identified in a single major serogroup. Strains from IATS serogroup 06 are more commonly implicated in clinical Pseudomonas infections than those from any other major serogroup. This serogroup contains at least five subtypes whose LPS 0-side chains share a common sequence of monosaccharide residues ( Fig. 1 ) but which are distinguished by differences in the mode of substitution or anomeric configuration of one or more sugars making up otherwise identical tetrasaccharide repeat units (15, 16) . Fisher immunotype 1 (IT-1), the most common serotype of the Fisher-DevlinGnabasek P. aeruginosa typing system, represents one of the five currently known IATS 06 subtypes. The growing evidence for antigenic diversity among P. aeruginosa strains at the subtype level poses important practical questions concerning the coverage provided by LPS-directed immunoprophylaxis and immunotherapy. The relevance of these issues is emphasized by recent studies that have evaluated the functional activities of antibodies induced by LPS-derived Pseudomonas vaccines solely on the basis of testing carried out against vaccine strains. In some cases, these strains represent only one of multiple subtypes from a given serogroup (3, 8, (30) (31) (32) 38 -(I -06a,6b   61  13  61  NH2 OAc NH2 -10% LPS. LPS was extracted from LPS-smooth P. aeruginosa strains by the phenol-water method of Westphal and Jann (46) to obtain principally smooth LPS molecules. LPS from rough strains AK1401 and PAC557 was extracted by the phenolchloroform-petroleum ether method as described before (11) . The extracted material was purified further as described previously (34) , using digestions with nucleases and pronase, ultracentrifugation, and chromatography over Sepharose CL4B. The resultant material contained 3 to 5% 2-keto-3-deoxyoctolusonic acid and had <1% contaminating nucleic acids and proteins. In addition, the LPS from the serogroup 06 strains were serologically analyzed by Y. Knirel, Moscow, Russia, using subtype-specific sera, and each LPS was found to have been extracted from the correct strain.
Preparation, screening, and evaluation of MAbs. MAbs were obtained as described previously (39) ) and goat anti-rabbit IgG-peroxidase conjugate, followed by incubation in the presence of 4-chloro-1-naphthol (Bio-Rad) as previously described (37) .
Human serum. Pre-and postimmunization sera from humans given 100 ,ig subcutaneously of a vaccine composed of the Fisher IT-1 high-molecular-weight polysaccharide were obtained as described previously (27) . Sera were obtained prior to immunization and 28 to 42 days postimmunization and were stored at -20°C.
ELISA employing human sera. Human sera were diluted in phosphate-buffered saline (PBS) containing 5% skim milk and 0.05% Tween 20 and added to microtiter wells of ELISA plates previously sensitized for 2 h at 37°C with P. aeruginosa LPS suspended at 10 jig of 0.04 M phosphate buffer (pH 7.2) per ml, and then the plates were washed and blocked at 4°C for at least 12 h with 5% skim milk. After the sera were incubated for 2 h at 37°C, plates were washed and a mixture of appropriate dilutions of alkaline-phosphatase-conjugated goat anti-human IgG, IgM, and IgA was added for 2 h at 37°C; plates were washed, and the para-nitro-O-phenylphosphate substrate was added. The OD405 was read at 60 min, and the titer was determined as described above for the MAbs, except that regression calculations were performed with the Statview SE + Graphics (Abacus Concepts, Inc., Berkeley, Calif.) program on a MacIntosh II computer.
ELISA inhibition. ELISA plates were sensitized with LPS from the various serogroup 06 strains as described above and blocked with 5% skim milk. Dilutions (1:100) of postimmunization human sera were added in duplicate to these wells, which were incubated for 1 h at 37°C; plates were washed, and then a 1:1,000 dilution of MAb LC3-2H2 (described in Results) was added. Control wells receiving human sera and no MAb and neither sera nor MAb were included. The MAb was left for 1 h at 37°C, and the wells were washed. Next we added alkaline phosphatase-conjugated goat anti-mouse gammachain-specific antibody diluted in PBS-5% skim milk-0.05% Tween 20 containing 2% normal human serum. This reagent was incubated for 1 h at 37°C. Plates were washed, substrate was added, and the OD of the wells was read at 30 to 60 min. Opsonophagocytic assay. Bacteria were grown for 4 h in tryptic soy broth, washed twice in RPMI, and suspended to a concentration of 2 x 107 CFU/ml in RPMI with 10% fetal bovine serum. Components of the assay included 0.1 ml of the bacterial suspension; 0.1 ml of dilutions of heat-inactivated (56°C, 30 min) pre-or postimmunization human serum or ascites fluid containing the MAb; 0.1 ml of 10% fresh, nonimmune human serum as a complement source, adsorbed previously with 1 mg of lyophilized serogroup 06 bacteria per ml of 10Cc complement at 4°C for 30 min; and 0.1 ml of RPMI containing 2 x 106 human peripheral blood leukocytes obtained from whole blood by dextran sedimentation. A sample was removed for dilution and bacterial enumeration at the start of the assay, the tubes were incubated for 90 min with end-over-end rotation, and then a sample was removed for dilution and enumeration of the surviving bacteria. Percent kills were calculated as described before (1). The titer was determined to be the highest serum dilution giving -50% kill of bacteria compared with the bacterial count of the control after 90 min of incubation without serum.
In vivo protection assays. " Reciprocal titer was determined by regression analysis of the linear portion of the dilution curve obtained when OD (x) was plotted against ascitic fluid dilution (y ); the resultant equation was solved for v (titer) when x = 0.5. mice immunized with the 06a,6c strain.) LB1-IC3 (IgG2a) reacted strongly with 06a,6b, weakly with 06a,6c, Fisher IT-l, and Habs 06, and not at all with 06a,6d. LD3-4D6 (IgM) was specific for 06a,6d. P6-1D2 (IgM) reacted strongly with Fisher IT-1 and Habs 06, weakly with 06a,6b, and not at all with 06a,6c and 06a,6d. None of the five MAbs exhibited ELISA binding activity (data not shown) against purified LPS from Fisher immunotypes 2 to 7 or from P. aeruginosa AK1401 and PAC557, rough mutant strains which express one of two structurally characterized P. aerliginosa core types and the D-rhamnan common antigen (2, 18, 41) .
Immunoblot analysis of MAbs against whole-cell extracts and purified LPS from various serogroup 06 subtypes (Fig. 2 The banding patterns observed on immunoblots were also of interest. A typical ladder pattern commonly associated with 0-side chain-containing LPS was produced by all of the MAbs except P6-2A2 (Fig. 2) . This MAb reacted predominantly with faster-migrating (lower-molecular-weight) material compared with that recognized by the other four MAbs; although some multiple banding was observed, it was associated primarily with lower-molecular-weight material and was not in a characteristic ladder pattern. The distinctive immunoblot patterns produced by various subtype-reactive MAbs are illustrated by the different staining configurations observed when IT-I whole-cell extract (lane 1 in each blot shown in Fig. 2 cytic killing of 06 subtype strains in the presence of human peripheral blood leukocytes and fresh human serum; subtype specificity coincided almost exactly with that demonstrated by ELISA ( Table 2 ). The correlation between opsonic (Table 2) and ELISA ( (27, 36) . Immune sera produced in response to immunization with LPS-derived material from this single subtype were evaluated for binding activity by ELISA (Table 4 ) and opsonic activity (Table 5 ) against all five serogroup 06 subtypes, including IT-1. All eight subjects demonstrated impressive increases in serum ELISA reactivity against LPS from all five serogroup 06 subtypes ( Table 4 ). The ELISA titers of individual subjects against various subtypes were similar; those individuals with high titers to one subtype antigen also tended to have high titers against the other subtypes (e.g., see subjects 3 and 8 in Table 4 ). Moreover, titers against the homologous IT-1 subtype were not consistently higher than those demonstrated against heterologous subtypes.
There was a strong correlation between ELISA reactivity (Table 4 ) and opsonic titers (Table 5 ) of postimmunization sera (P < 0.001 by Kendall rank correlation). While seven of eight subjects had no detectable preimmunization opsonic activity against any of the subtype strains, all subjects had readily detectable opsonic activity against all five subtype strains after immunization. As in the case of ELISA reactivity, most subjects exhibited similar titers against the various serogroup 06 subtypes. Inhibition by postimmunization sera of binding by MAb LC3-2H2 to serogroup 06 subtype LPS. MAb LC3-2H2 reacts with LPS from all five serogroup 06 subtypes and thus may recognize a common epitope shared by all five subtypes. We investigated whether this putative common epitope was recognized by sera from five subjects immunized with IT-1 highmolecular-weight polysaccharide vaccine by evaluating the ability of each serum to inhibit the ELISA reactivity of MAb LC3-2H2 with each of the 06 subtype antigens. All of the immune sera inhibited MAb binding to multiple LPS subtypes (range, 31 to 65% inhibition) (Fig. 3) . Two of the serum samples inhibited MAb binding to all five subtypes, and the remaining three serum samples appeared to inhibit MAb binding to four of five subtype antigens. In each of the three instances in which MAb reactivity did not appear to be inhibited by immune serum, a different antigen and a different serum were involved (Fig. 3) . These data suggest that the basis for the observed cross-reactivity of immune sera produced through immunization of human subjects with IT-1 highmolecular-weight polysaccharide may be the induction of antibody that recognized the common epitope recognized by MAb LC3-2H2. A potential concern stemming from demonstrated subtyperelated differences in 0-side chain structure and antigenicity, and corresponding variations in the subtype specificity of 0-side chain-reactive MAbs, is the immunoprophylactic or therapeutic coverage provided by 0-side chain-based vaccines (5, 6, 7, 28, 43) or MAbs directed to these structures (12, 24, 25) . For example, an octavalent P. aeruginosa 0-polysaccharide-toxin A conjugate vaccine was recently evaluated for immunogenicity in humans solely on the basis of antibodies induced against prototype strains used in making the vaccine (6, 44) . The possible subtype specificity of immune responses to this vaccine was thus ignored. Likewise, animal and human immune responses to P. aeruginosa high-molecular-weight polysaccharide vaccines have been evaluated primarily against those strains employed in vaccine preparation (27, 29) . Similarly, a cocktail of human MAbs directed against LPS from five different P. aeruginosa serogroups (42) appears to have been screened against a single strain from each of the represented serogroups, raising the possibility that one or more of the component MAbs is directed against subtype-rather than serogroup-specific determinants.
DISCUSSION
It was encouraging that despite the restrictive subtype specificity of some MAbs in this study (e.g., LB1-1C3, LC3-4D6, and P6-1D2), others (e.g., P6-2A2 and LC3-2H2) appeared to cross-react more broadly among different serogroup 06 subtypes. For practical purposes, in fact, since LC3-2H2 reacted with all 06 LPS subtypes, it should be considered a serogroup-rather than a subtype-specific antibody, while the epitope recognized by LC3-2H2 is properly seen as a serogroup rather than a subtype determinant.
The demonstration of a murine MAb capable of recognizing an LPS determinant apparently common to all subtypes of IATS serogroup 06 paralleled the finding that human subjects immunized with a high-molecular-weight polysaccharide vaccine derived from Fisher IT-1 P. aeruginosa (one of five 06 subtypes) exhibited similar serum antibody responses to all 06 subtypes in terms of both binding activity and opsonic function. These parallel observations were linked by the demonstration that postimmunization sera from human subjects vaccinated with the Fisher IT-1 high-molecular-weight polysaccharide were capable of inhibiting binding by MAb LC3-2H2 to all serogroup 06 subtype antigens. Together, these observations suggest the feasibility of producing serogroup-specific MAbs and polyclonal antibodies to epitopes shared by various LPS subtypes. Further suggested is the likelihood that the crossreactive serum antibody response induced by immunization with the Fisher IT-1 high-molecular-weight polysaccharide vaccine was based at least in part on antibodies similar or identical in epitope specificity to that of MAb LC3-2H2.
